MHRAsafety guidance54% confidence
Opportunities for patients and the public to be involved in the work of the MHRA
Source: MHRA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Merck.
Regulatory Analysis
How we engage and involve patients and the public in our regulatory decision-making.
Supporting Context
- Therapeutic area
- Infectious Disease · HIV
- Sub-indication
- General
Related signal: FDA Approves Merck’s IDVYNSO for Virologically Suppressed HIV-1 Patients